# Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

> clinical trial · VERIFIED · 2026-07-23

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Malignant Female Reproductive System Neoplasm

- Company: National Cancer Institute (NCI)
- Sector: Malignant Female Reproductive System Neoplasm
- Primary source: https://clinicaltrials.gov/study/NCT06126276

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.